The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | FIBROMET preliminary results: metformin promising for primary MF
Sara Olalla Saad, PhD, University of Campinas & Hemocentro – Unicamp, Campinas, Brazil, discusses the preliminary results from an open label phase 2 trial, FIBROMET, evaluating the effects of metformin on bone marrow fibrosis and disease progression in primary myelofibrosis (PMF) patients. Prof. Saad highlights how this re-use of an old drug would give a cheaper and more accessible treatment, and outlines the next steps for the study. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
